Your account is not claimed yet. You can sign up with ORCID to claim your account.

Michael A Webster-Clark (Michael Webster-Clark)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Venues

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Michael A Webster-Clark, Sengwee Toh, Jonathan Arnold, Kathleen M McTigue, Thomas Carton, Robert W Platt
External validity in distributed data networks. Pharmacoepidemiology and drug safety (2023)
Michael A Webster-Clark, Panagiotis Mavros, Elizabeth M Garry, Til Stürmer, Shahar Shmuel, Jessica C Young, Cynthia J Girman
Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiology and drug safety 31 (7) (2022)
Emilie D Duchesneau, Bradford E Jackson, Michael A Webster-Clark, Jennifer L Lund, Katherine E Reeder-Hayes, Anna Maria Napoles, Paula D Strassle
The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 31 (11) (2022)
Di Shu, Michael A Webster-Clark, Robert W Platt, Sengwee Toh
Meta-analysis with sample-standardization in multi-site studies. Pharmacoepidemiology and drug safety (2022)
Michael A Webster-Clark, Alexander P Keil, Hanna K Sanoff, Til Stürmer, Daniel Westreich, Jennifer L Lund
Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International journal of cancer 149 (2) (2021)
Michael A Webster-Clark, Ting-Ying Huang, Laura Hou, Sengwee Toh
Translating claims-based CHA2 DS2 -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategies. Pharmacoepidemiology and drug safety 29 (4) (2020)
Michael A Webster-Clark, Til Stürmer, Tiansheng Wang, Kenneth Man, Danica Marinac-Dabic, Kenneth J Rothman, Alan R Ellis, Mugdha Gokhale, Mark Lunt, Cynthia Girman, Robert J Glynn
Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in medicine 40 (7) (2020)
Michael A Webster-Clark
Ways COVID-19 may impact unrelated pharmacoepidemiologic research using routinely collected data. Pharmacoepidemiology and drug safety 30 (3) (2020)
Michael A Webster-Clark, Til Stürmer, Jessie K Edwards, Charles Poole, Ross J Simpson, Jennifer L Lund
Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. Pharmacoepidemiology and drug safety 29 (8) (2020)
Jennifer L Lund, Michael A Webster-Clark, Sharon Peacock Hinton, Shahar Shmuel, Til Stürmer, Hanna K Sanoff
Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach. Pharmacoepidemiology and drug safety 29 (12) (2020)

Michael A Webster-Clark.css-eqlu8i{font-size:small;padding-left:4px;} (Michael Webster-Clark)

Publication Activity (10 Years)

Top Topics

Top Venues

Michael A Webster-Clark (Michael Webster-Clark)